Skip to main content

Clinical Trials Using Allogeneic PD-L1 Tumor-targeted High-affinity Natural Killer Cells

Review the clinical trials studying allogeneic pd-l1 tumor-targeted high-affinity natural killer cells on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-2 of 2

PD-L1 t-haNK with N-803 and Cetuximab for the Treatment of Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active
Location: 2 locations
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland